Defining Phenotypes in COPD: An Aid to Personalized Healthcare
- 357 Downloads
The diagnosis of chronic obstructive pulmonary disease (COPD) is based on a post-bronchodilator fixed forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <70 % ratio and the presence of symptoms such as shortness of breath and productive cough. Despite the simplicity in making a diagnosis of COPD, this morbid condition is very heterogeneous, and at least three different phenotypes can be recognized: the exacerbator, the emphysema–hyperinflation and the overlap COPD–asthma. These subgroups show different clinical and radiological features. It has been speculated that there is an enormous variability in the response to drugs among the COPD phenotypes, and it is expected that subjects with the same phenotype will have a similar response to each specific treatment. We believe that phenotyping COPD patients would be very useful to predict the response to a treatment and the progression of the disease. This personalized approach allows identification of the right treatment for each COPD patient, and at the same time, leads to improvement in the effectiveness of therapies, avoidance of treatments not indicated, and reduction in the onset of adverse effects. The objective of the present review is to report the current knowledge about different COPD phenotypes, focusing on specific treatments for each subgroup. However, at present, COPD phenotypes have not been studied by randomized clinical trials and therefore we hope that well designed studies will focus on this topic.
KeywordsChronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Patient Tiotropium Chronic Obstructive Pulmonary Disease Exacerbation Roflumilast
Acknowledgements and Disclosures
- 2.Global Initiative for Chronic Obstructive Pulmonary Disease. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf.
- 5.American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema: a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis. 1962;85:762–8.Google Scholar
- 6.The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis. 1985;132(1):182–5.Google Scholar
- 23.Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10. doi: 10.1186/1465-9921-11-10.PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C. Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Therapy. 2008;25(10):1019–30. doi: 10.1007/s12325-008-0105-2.
- 43.Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–5. doi: 10.1016/S0140-6736(00)02872-5.PubMedCrossRefGoogle Scholar
- 53.Paige M, Burdick MD, Kim S, Xu J, Lee JK, Michael Shim Y. Pilot analysis of the plasma metabolite profiles associated with emphysematous chronic obstructive pulmonary disease phenotype. Biochem Biophys Res Commun. 2011;413(4):588–93. doi: 10.1016/j.bbrc.2011.09.006.PubMedCentralPubMedCrossRefGoogle Scholar
- 54.Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA, et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PloS one. 2009;4(8):e6865. doi: 10.1371/journal.pone.0006865.PubMedCentralPubMedCrossRefGoogle Scholar
- 61.National Institute for Health and Care Excellence. http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf.
- 66.Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol. 2013;131(3):627–34; quiz 35. doi: 10.1016/j.jaci.2013.01.010.
- 67.Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Primary Care Respiratory Journal: Journal of the General Practice Airways Group. 2013;22(1):117–21, 1471–4418.Google Scholar